第 1 到 190 筆結果,共 190 筆。

公開日期標題作者來源出版物scopusWOS全文
12024Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyCapdevila, Jaume; Krajewska, Jolanta; Hernando, Jorge; Robinson, Bruce; Sherman, Steven I; Jarzab, Barbara; CHIA-CHI LIN ; Vaisman, Fernanda; Hoff, Ana O; Hitre, Erika; Bowles, Daniel W; Williamson, Denise; Levytskyy, Roman; Oliver, Jennifer; Keam, Bhumsuk; Brose, Marcia SThyroid : official journal of the American Thyroid Association
22024Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human StudyKelly, William K; Danila, Daniel C; CHIA-CHI LIN ; Lee, Jae-Lyun; Matsubara, Nobuaki; Ward, Patrick J; Armstrong, Andrew J; Pook, David; Kim, Miso; Dorff, Tanya B; Fischer, Stefanie; Lin, Yung-Chang; Horvath, Lisa G; Sumey, Christopher; Yang, Zhao; Jurida, Gabor; Smith, Kristen M; Connarn, Jamie N; Penny, Hweixian L; Stieglmaier, Julia; Appleman, Leonard JCancer discovery
32024Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW StudySubbiah, Vivek; Hu, Mimi I; Mansfield, Aaron S; Taylor, Matthew H; Schuler, Martin; Zhu, Viola W; Hadoux, Julien; Curigliano, Giuseppe; Wirth, Lori; Gainor, Justin F; Alonso, Guzman; Adkins, Douglas; Godbert, Yann; Ahn, Myung-Ju; Cassier, Philippe A; Cho, Byoung Chul; CHIA-CHI LIN ; Zalutskaya, Alena; Barata, Teresa; Trask, Peter; Scalori, Astrid; Bordogna, Walter; Heinzmann, Sebastian; Brose, Marcia SThyroid : official journal of the American Thyroid Association
42024Clinical practice consensus for the diagnosis and management of melanoma in TaiwanWu, Chiao-En; YI-HUA LIAO ; Wu, Cheng-Lin; RUOH-FANG YEN ; CHIA-CHI LIN ; Yang, Muh-Hwa; Yen, Chueh-Chuan; Su, Wu-Chou; Yen, Chia-Jui; Chang, Yi-Fang; Wu, Ming-Fang; Yang, Youngsen; Lin, Chen-Yuan; Yang, Wen-Chi; Wang, Hui-Ching; Li, Cheng-Yuan; Ho, Yin-Yu; Chang, Yao-Yu; Wu, Chieh-Shan; Hsu, Hsiu-Cheng; Chen, Kuang-Hua; Huang, Yenlin; Chen, Chih-Jung; Chuang, Pei-Ju; Lai, Yung-Chi; Huang, Yu-Yi; Tseng, Neng-Chuan; Huang, Yi-Ting; CHIA-YU CHU ; Wen-Cheng Chang, JohnJournal of the Formosan Medical Association = Taiwan yi zhi20
52024A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesCHIA-CHI LIN ; Garralda, Elena; Schöffski, Patrick; Hong, David S; Siu, Lillian L; Martin, Miguel; Maur, Michela; Hui, Rina; Soo, Ross A; Chiu, Joanne; Zhang, Tian; Ma, Brigette; Kyi, Chrisann; Tan, Daniel Sw; Cassier, Philippe A; Sarantopoulos, John; Weickhardt, Andrew; Carvajal, Richard D; Spratlin, Jennifer; Esaki, Taito; Rolland, Fréderic; Akerley, Wallace; Deschler-Baier, Barbara; Rispoli, Lawrence; Samant, Tanay S; Chowdhury, Niladri Roy; Gusenleitner, Daniel; Kwak, Eunice L; Askoxylakis, Vasileios; De Braud, FilippoOncoimmunology10
62023Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumorsBauer, Todd M; Santoro, Armando; CHIA-CHI LIN ; Garrido-Laguna, Ignacio; Joerger, Markus; Greil, Richard; Spreafico, Anna; Yau, Thomas; Goebeler, Maria-Elisabeth; Hütter-Krönke, Marie Luise; Perotti, Antonella; Juif, Pierre-Eric; Lu, Darlene; Barys, Louise; Cremasco, Viviana; Pelletier, Marc; Evans, Helen; Fabre, Claire; Doi, ToshikikoJournal for immunotherapy of cancer1
72023A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancerMacaulay, Valentine M; Lord, Simon; Hussain, Syed; Maroto, José Pablo; Jones, Robert Hugh; Climent, Miguel Ángel; Cook, Natalie; CHIA-CHI LIN ; Wang, Shian-Shiang; Bianchini, Diletta; Bailey, Mark; Schlieker, Laura; Bogenrieder, Thomas; de Bono, JohannBritish journal of cancer11
82023Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancerJHE-CYUAN GUO ; Hsu, Chia-Lang; MIN-SHU HSIEH ; CHIA-CHI LIN ; TA-CHEN HUANG ; HUNG-YANG KUO ; YU-YUN SHAO ; CHIH-HUNG HSU Thoracic cancer00
92023Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLCZhou, Qing; Soo, Ross A; Chang, Gee-Chen; Chiu, Chao-Hua; Hayashi, Hidetoshi; Kim, Sang-We; Teraoka, Shunsuke; Goto, Yasushi; Zhou, Jianying; Ho-Fun Lee, Victor; Kim, Dong-Wan; Han, Baohui; Chung Man Ho, James; CHIA-CHI LIN ; Lu, Shun; Polli, Anna; Calella, Anna Maria; Martini, Jean-François; Wong, Chew Hooi; Mok, Tony; Kim, Hye Ryun; Wu, Yi-LongJTO clinical and research reports30
102023Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 studyOh, Do-Youn; Algazi, Alain; Capdevila, Jaume; Longo, Federico; Miller, Wilson; Chun Bing, Jerry Tan; Bonilla, Carlos Eduardo; Chung, Hyun Cheol; Guren, Tormod K; CHIA-CHI LIN ; Motola-Kuba, Daniel; Shah, Manisha; Hadoux, Julien; Yao, Lili; Jin, Fan; Norwood, Kevin; Lebellec, LoïcCancer53
112022Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trialBrose, Marcia S; Robinson, Bruce G; Sherman, Steven I; Jarzab, Barbara; CHIA-CHI LIN ; Vaisman, Fernanda; Hoff, Ana O; Hitre, Erika; Bowles, Daniel W; Sen, Suvajit; Oliver, Jennifer W; Banerjee, Kamalika; Keam, Bhumsuk; Capdevila, JaumeCancer11
122022Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter studySimonelli, M; Garralda, E; Eskens, F; Gil-Martin, M; Yen, C-J; Obermannova, R; Chao, Y; Lonardi, S; Melichar, B; Moreno, V; Yu, M-L; Bongiovanni, A; Calvo, E; Rottey, S; Machiels, J-P; Gonzalez-Martin, A; Paz-Ares, L; Chang, C-L; Mason, W; CHIA-CHI LIN ; Reardon, D A; Vieito, M; Santoro, A; Meng, R; Abbadessa, G; Menas, F; Lee, H; Liu, Q; Combeau, C; Ternes, N; Ziti-Ljajic, S; Massard, CESMO open88
132022Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase InhibitorsWu, Tsung-Che; CHIA-CHI LIN Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2
142022Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI)Brose, Marcia S; Smit, Johannes W A; CHIA-CHI LIN ; Tori, Masayuki; Bowles, Daniel W; Worden, Francis; Shen, Daniel Hueng-Yuan; Huang, Shih-Ming; Tsai, Hui-Jen; Alevizaki, Maria; Peeters, Robin P; Takahashi, Shunji; Rumyantsev, Pavel; Guan, Rongjin; Babajanyan, Svetlana; Ozgurdal, Kirhan; Sugitani, Iwao; Pitoia, Fabian; Lamartina, LiviaThyroid : official journal of the American Thyroid Association65
152022Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapyTA-CHEN HUANG ; Liang C.-W.; Li Y.-I.; GUO, JHE-CYUAN ; CHIA-CHI LIN ; Chen Y.-J.; ANN-LII CHENG ; CHIH-HUNG HSU Journal of Cancer Research and Clinical Oncology22
162022Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trialSoo, Ross A; Huat Tan, Eng; Hayashi, Hidetoshi; Seto, Takashi; CHIA-CHI LIN ; Ou, Sai-Hong Ignatius; Kim, Dong-Wan; Liu, Geoffrey; Abbattista, Antonello; Martini, Jean-François; Hooi Wong, Chew; Toffalorio, Francesca; Solomon, Benjamin JLung cancer (Amsterdam, Netherlands)9
172022A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsChan, Stephen L; Schuler, Martin; Kang, Yoon-Koo; Yen, Chia-Jui; Edeline, Julien; Choo, Su Pin; CHIA-CHI LIN ; Okusaka, Takuji; Weiss, Karl-Heinz; Macarulla, Teresa; Cattan, Stéphane; Blanc, Jean-Frederic; Lee, Kyung-Hun; Maur, Michela; Pant, Shubham; Kudo, Masatoshi; Assenat, Eric; Zhu, Andrew X; Yau, Thomas; Lim, Ho Yeong; Bruix, Jordi; Geier, Andreas; Guillén-Ponce, Carmen; Fasolo, Angelica; Finn, Richard S; Fan, Jia; Vogel, Arndt; Qin, Shukui; Riester, Markus; Katsanou, Vasiliki; Chaudhari, Monica; Kakizume, Tomoyuki; Gu, Yi; Porta, Diana Graus; Myers, Andrea; Delord, Jean-PierreJournal of experimental & clinical cancer research : CR18
182022B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaJHE-CYUAN GUO ; Hsu, Chia-Lang; YEN-LIN HUANG ; CHIA-CHI LIN ; TA-CHEN HUANG ; Wu, I-Chen; Lin, Chen-Yuan; Lien, Ming-Yu; HUNG-YANG KUO ; ANN-LII CHENG ; CHIH-HUNG HSU Frontiers in oncology11
192022Immunotherapy in anaplastic thyroid cancer: Case seriesSHYANG-RONG SHIH ; Chen, Kuan-Hua; Lin, Kuan-Yu; PAN-CHYR YANG ; KUEN-YUAN CHEN ; CHUN-WEI WANG ; Chun-Nan Chen ; CHIH-FENG LIN ; CHIA-CHI LIN Journal of the Formosan Medical Association = Taiwan yi zhi56
202022Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological MalignanciesShimizu, Toshio; Kuboki, Yasutoshi; CHIA-CHI LIN ; Yonemori, Kan; Yanai, Tomoko; Faller, Douglas V; Dobler, Lwona; Gupta, Neeraj; Sedarati, Farhad; Kim, Kyu-PyoTargeted oncology00
212022Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimensWEI-LI MA ; CHIA-CHI LIN ; FENG-MING HSU ; JANG-MING LEE ; JIN-SHING CHEN ; YEN-LIN HUANG ; YIH-LEONG CHANG ; Chang, Chin-Hao; CHIH-HSIN YANG Cancer medicine22
222022Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib StudyAbdul Razak, Albiruni R; Bauer, Sebastian; Suarez, Cristina; CHIA-CHI LIN ; Quek, Richard; Hütter-Krönke, Marie Luise; Cubedo, Ricardo; Ferretti, Stephane; Guerreiro, Nelson; Jullion, Astrid; Orlando, Elena J; Clementi, Giorgia; Sand Dejmek, Janna; Halilovic, Ensar; Fabre, Claire; Blay, Jean-Yves; Italiano, AntoineClinical cancer research : an official journal of the American Association for Cancer Research19
232022Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaStein, Eytan M; DeAngelo, Daniel J; Chromik, Jörg; Chatterjee, Manik; Bauer, Sebastian; CHIA-CHI LIN ; Suarez, Cristina; de Vos, Filip; Steeghs, Neeltje; Cassier, Philippe A; Tai, David; Kiladjian, Jean-Jacques; Yamamoto, Noboru; Mous, Rogier; Esteve, Jordi; Minami, Hironobu; Ferretti, Stephane; Guerreiro, Nelson; Meille, Christophe; Radhakrishnan, Rajkumar; Pereira, Bernard; Mariconti, Luisa; Halilovic, Ensar; Fabre, Claire; Carpio, CeciliaClinical cancer research : an official journal of the American Association for Cancer Research25
242022Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinomaJHE-CYUAN GUO ; CHIA-CHI LIN ; Hsu, Chia-Lang; TA-CHEN HUANG ; HUNG-YANG KUO ; Lin, Chen-Yuan; Lien, Ming-Yu; ANN-LII CHENG ; CHIH-HUNG HSU Esophagus : official journal of the Japan Esophageal Society00
252022A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological MalignanciesShimizu T.; Kuboki Y.; CHIA-CHI LIN ; Yonemori K.; Yanai T.; Faller D.V.; Dobler L.; Gupta N.; Sedarati F.; Kim K.-P.Targeted Oncology45
262022Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter studyZucali P.A.; CHIA-CHI LIN ; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN ; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J.Journal for ImmunoTherapy of Cancer2518
272022First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinomaItaliano A.; Cassier P.A.; CHIA-CHI LIN ; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V.Cancer Immunology, Immunotherapy45
282021Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor SitesGUO, JHE-CYUAN ; Lin, Chen Yuan; CHIA-CHI LIN ; TA-CHEN HUANG ; Lien, Ming Yu; LI-CHUN LU ; HUNG-YANG KUO ; CHIH-HUNG HSU ONCOLOGY (United States)11
292021Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung CancerDziadziuszko, Rafal; Krebs, Matthew G; De Braud, Filippo; Siena, Salvatore; Drilon, Alexander; Doebele, Robert C; Patel, Manish R; Cho, Byoung Chul; Liu, Stephen V; Ahn, Myung-Ju; Chiu, Chao-Hua; Farago, Anna F; CHIA-CHI LIN ; Karapetis, Christos S; Li, Yu-Chung; Day, Bann-Mo; Chen, David; Wilson, Timothy R; Barlesi, FabriceJournal of clinical oncology : official journal of the American Society of Clinical Oncology7457
302021Endoscopic ultrasound ablation in a patient with multiple metastatic pancreatic tumors from adrenocorticotropic hormone-producing thymic neuroendocrine neoplasmChang, Ling-Kai; Chen, Kuan-Chih; MEI-FANG CHENG ; CHIA-CHI LIN ; HSIU-PO WANG ; Sung, Chia-Tung; Chen, Jou-Ho; RUOH-FANG YEN ; CHIA-LIN HSU ; SHYANG-RONG SHIH Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society22
312021Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves' OrbitopathySHYANG-RONG SHIH ; SHU-LANG LIAO ; Shih, Chih-Wei; YI-HSUAN WEI ; Lu, Ting-Xuan; Chou, Chien-Hsiang; Yen, Er-Yen; YI-CHENG CHANG ; CHIA-CHI LIN ; Chi, Yu-Chiao; WEI-SHIUNG YANG ; FENG-CHIAO TSAI Ocular immunology and inflammation44
322021Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLCBIN-CHI LIAO ; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHING-YAO YANG ; TZU-HSIU TSAI ; WEI-YU LIAO ; CHAO-CHI HO ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHONG-JEN YU ; Soo, Ross A; CHIH-HSIN YANG JTO clinical and research reports20
332021Clinical development of colony-stimulating factor 1 receptor (Csf1r) inhibitorsCHIA-CHI LIN Journal of Immunotherapy and Precision Oncology210
342021Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsHollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; CHIA-CHI LIN ; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J.Clinical Cancer Research2421
352021Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 ConsortiumShimizu T.; Kim D.-W.; Loong H.H.; CHIA-CHI LIN ; Ng M.C.H.; Yamamoto N.; Ma B.; Tan D.S.W.Asia-Pacific Journal of Clinical Oncology21
362021Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialBrose M.S.; Robinson B.; Sherman S.I.; Krajewska J.; CHIA-CHI LIN ; Vaisman F.; Hoff A.O.; Hitre E.; Bowles D.W.; Hernando J.; Faoro L.; Banerjee K.; Oliver J.W.; Keam B.; Capdevila J.The Lancet Oncology111101
372021Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab DeruxtecanYin O.; Iwata H.; CHIA-CHI LIN ; Tamura K.; Watanabe J.; Wada R.; Kastrissios H.; AbuTarif M.; Garimella T.; Lee C.; Zhang L.; Shahidi J.; LaCreta F.Clinical Pharmacology and Therapeutics1715
382021Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in AsiaCHIA-CHI LIN ; Doi T.; Muro K.; Hou M.-M.; Esaki T.; Hara H.; Chung H.C.; Helwig C.; Dussault I.; Osada M.; Kondo S.Targeted Oncology1612
392021Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studySubbiah V.; Hu M.I.; Wirth L.J.; Schuler M.; Mansfield A.S.; Curigliano G.; Brose M.S.; Zhu V.W.; Leboulleux S.; Bowles D.W.; Baik C.S.; Adkins D.; Keam B.; Matos I.; Garralda E.; Gainor J.F.; Lopes G.; CHIA-CHI LIN ; Godbert Y.; Sarker D.; Miller S.G.; Clifford C.; Zhang H.; Turner C.D.; Taylor M.H.The Lancet Diabetes and Endocrinology173140
402021Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase InhibitorsPark K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; CHIA-CHI LIN JTO Clinical and Research Reports40
412021Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumorsCurigliano G.; Gelderblom H.; Mach N.; Doi T.; Tai D.; Forde P.M.; Sarantopoulos J.; Bedard P.L.; CHIA-CHI LIN ; Stephen Hodi F.; Wilgenhof S.; Santoro A.; Sabatos-Peyton C.A.; Longmire T.A.; Xyrafas A.; Sun H.; Gutzwiller S.; Manenti L.; Naing A.Clinical Cancer Research120108
422021Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumorsTakahashi S.; Karayama M.; Takahashi M.; Watanabe J.; Minami H.; Yamamoto N.; Kinoshita I.; CHIA-CHI LIN ; Im Y.-H.; Achiwa I.; Kamiyama E.; Okuda Y.; Lee C.; Bang Y.-J.Clinical Cancer Research1211
432021Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell TumorsLewis J.H.; Gelderblom H.; van de Sande M.; Stacchiotti S.; Healey J.H.; Tap W.D.; Wagner A.J.; Pousa A.L.; Druta M.; CHIA-CHI LIN ; Baba H.A.; Choi Y.; Wang Q.; Shuster D.E.; Bauer S.Oncologist2221
442021Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid TumorsShiah H.-S.; Chiang N.-J.; CHIA-CHI LIN ; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T.Oncologist20
452021Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trialPatnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; CHIA-CHI LIN ; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J.Clinical Cancer Research2317
462020Novel trial designs for early phase clinical trialsCHIA-CHI LIN Phase I Oncology Drug Development
472020Rational combination with an immunotherapy backbone in genitourinary cancersJHE-CYUAN GUO ; CHIA-CHI LIN Urological Science33
482020Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohortsBang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; CHIA-CHI LIN ; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B.Cancer Science4335
492020Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibCHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Liu, Yi-Nan; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; BIN-CHI LIAO ; Hsu, Chia-Chi; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU Oncologist1515
502020Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitorsCHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; Chia-Chi Hsu; BIN-CHI LIAO ; Wei-Hsun Hsu; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU European Journal of Cancer5549
512020Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsDrilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; CHIA-CHI LIN ; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C.The Lancet Oncology308250
522020Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)Bang Y.-J.; Golan T.; Dahan L.; Fu S.; Moreno V.; Park K.; Geva R.; De Braud F.; Wainberg Z.A.; Reck M.; Goff L.; Laing N.; Mi G.; Oliveira J.M.; Wasserstrom H.; CHIA-CHI LIN European Journal of Cancer8580
532020Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumorsDesai J.; Deva S.; Lee J.S.; CHIA-CHI LIN ; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M.Journal for ImmunoTherapy of Cancer7973
542020Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerPeters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; CHIA-CHI LIN ; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D.Lung Cancer1412
552020Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialPetrylak D.P.; de Wit R.; Chi K.N.; Drakaki A.; Sternberg C.N.; Nishiyama H.; Castellano D.; Hussain S.A.; Fl?chon A.; Bamias A.; Yu E.Y.; Lee H.J.; Park S.H.; Rha S.Y.; Kim Y.J.; Lee Y.-G.; Vazquez Cort?s L.; Lorena Urzua Flores C.; Blaisse R.J.B.; Erdkamp F.L.G.; Aarts M.J.B.; van der Heijden M.S.; Wojcik-Tomaszewska J.; Tomczak P.; Sikora-Kupis B.; Schenker M.; Herzal A.A.; Udrea A.A.; Karlov P.; Fomkin R.; Gajate Borau P.; Grande E.; Matsubara N.; Delgado Mignorance J.I.; Su Y.-L.; Li J.-R.; Lin C.-L.; CHIA-CHI LIN ; Yeh S.-P.; Erman M.; Urun Y.; Golovko Y.; Bondarenko I.; Alekseev B.; Sinielnikov I.; Crabb S.J.; Syndikus I.; Huddart R.; Sundar S.; Chowdhury S.; Sarwar N.; Flaig T.W.; Pan C.X.; Schwarz J.K.; Necchi A.; Cultrera J.L.; Acs P.I.; Hainsworth J.D.; Herms B.T.; Lawler W.E.; Lowe T.E.; G?czi L.; Ou Y.-C.; Coskun H.S.; Su W.-P.; Bedke J.; Gakis G.; Percent I.J.; Lee J.-L.; Tucci M.; Semenov A.; Laestadius F.; Peer A.; Tortora G.; Safina S.; Garcia del Muro X.; Rodriguez-Vida A.; Cicin I.; Harputluoglu H.; Tagawa S.T.; Vaishampayan U.; Aragon-Ching J.B.; Hamid O.; Liepa A.M.; Wijayawardana S.; Russo F.; Walgren R.A.; Zimmermann A.H.; Hozak R.R.; Bell-McGuinn K.M.; Powles T.; Wong S.-L.S.; Tan T.H.; Hovey E.J.; Clay T.D.; Wan Ng S.S.; Rutten A.; Machiels J.-P.; Dumez H.; Cheng S.Y.-S.; Ferrario C.; Sengeloev L.; Jensen N.V.; Thibault C.; Laguerre B.; Joly F.; Culine S.; Becht C.; Niegisch G.; St?ckle M.; Grimm M.-O.; Schwentner C.A.; Schultze-Seemann W.; Kalofonos H.; Mavroudis D.; Papandreou C.; Karavasilis V.; R?v?sz J.; Rosenbaum E.; Leibowitz-Amit R.; Kejzman D.; Sarid D.; Scagliotti G.V.; Bracarda S.; Massari F.; Osawa T.; Miyajima N.; Shinohara N.; Fukuta F.; Ohyama C.; Obara W.; Yamashita S.; Tomita Y.; Kawai K.; Fukasawa S.; Oyama M.; Yonese J.; Nagata M.; Uemura M.; Nishimura K.; Kawakita M.; Tsunemori H.; Hashine K.; Inokuchi J.; Yokomizo A.; Nagamori S.The Lancet Oncology5851
562020Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 TrialPaz-Ares L.; Kim T.M.; Vicente D.; Felip E.; Lee D.H.; Lee K.H.; CHIA-CHI LIN ; Flor M.J.; Di Nicola M.; Alvarez R.M.; Dussault I.; Helwig C.; Ojalvo L.S.; Gulley J.L.; Cho B.C.Journal of Thoracic Oncology112101
572020An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLCZhu, Viola W; YEN-TING LIN ; Kim, Dong-Wan; Loong, Herbert H; Nagasaka, Misako; To, Hao; Ang, Yvonne Li-En; Ock, Chan-Young; Tchekmedyian, Nishan; Ou, Sai-Hong Ignatius; Syn, Nicholas L; Reungwetwattana, Thanyanan; CHIA-CHI LIN ; Soo, Ross AJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer4536
582020Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib StudyCHIA-CHI LIN ; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; CHIUN HSU Oncologist54
592020Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE TrialDrakaki A.; Kirby C.J.; Van Der Heijden M.S.; Petrylak D.P.; Powles T.; Chi K.N.; Fl?chon A.; Necchi A.; G?czi L.; Lee J.-L.; Gakis G.; Bracarda S.; Chowdhury S.; CHIA-CHI LIN ; Keizman D.; Vaishampayan U.N.; Zimmermann A.H.; Bell-Mcguinn K.; Castellano D.Bladder Cancer22
602020Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumoursde Bono J.; CHIA-CHI LIN ; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE ; CHIH-HUNG HSU ; CHIH-HSIN YANG ; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG British Journal of Cancer1917
612020A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignanciesYamamoto N.; Ryoo B.-Y.; Keam B.; Kudo M.; CHIA-CHI LIN ; Kunieda F.; Ball H.A.; Moran D.; Komatsu K.; Takeda K.; Fukuda M.; Furuse J.; Morita S.; Doi T.Investigational New Drugs1514
622020An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid CancerBible K.C.; Menefee M.E.; CHIA-CHI LIN ; Millward M.J.; Maples W.J.; Goh B.C.; Karlin N.J.; Kane M.A.; Adkins D.R.; Molina J.R.; Donehower R.C.; Lim W.-T.; Flynn P.J.; Richardson R.L.; Traynor A.M.; Rubin J.; Lorusso P.M.; Smallridge R.C.; Burton J.K.; Suman V.J.; Kumar A.; Voss J.S.; Rumilla K.M.; Kipp B.R.; Chintakuntlawar A.V.; Harris P.; Erlichman C.Thyroid1513
632020A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumorsJIH-HSIANG LEE ; WEI-WU CHEN ; CHIH-HUNG HSU ; Yen Y.-H.; CHIH-HSIN YANG ; ANN-LII CHENG ; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; CHIA-CHI LIN Investigational New Drugs3836
642020Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLCTan W.L.; Chua K.L.M.; CHIA-CHI LIN ; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG ; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F.Journal of Thoracic Oncology3230
652020Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanomaSi L.; Zhang X.; Shin S.J.; Fan Y.; CHIA-CHI LIN ; Kim T.M.; Dechaphunkul A.; Maneechavakajorn J.; Wong C.S.; Ilankumaran P.; Lee D.-Y.; Gasal E.; Li H.; Guo J.European Journal of Cancer128
662020Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumorsStrickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; CHIA-CHI LIN ; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K.Molecular Cancer Therapeutics1614
672020PD-1 blockade in anaplastic thyroid carcinomaCapdevila J.; Wirth L.J.; Ernst T.; Aix S.P.; CHIA-CHI LIN ; Ramlau R.; Butler M.O.; Delord J.-P.; Gelderblom H.; Ascierto P.A.; Fasolo A.; F?hrer D.; H?tter-Kr?nke M.L.; Forde P.M.; Wrona A.; Santoro A.; Sadow P.M.; Szpakowski S.; Wu H.; Bostel G.; Faris J.; Cameron S.; Varga A.; Taylor M.Journal of Clinical Oncology151126
682020A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsNaing A.; Gainor J.F.; Gelderblom H.; Forde P.M.; Butler M.O.; CHIA-CHI LIN ; Sharma S.; Ochoa De Olza M.; Varga A.; Taylor M.; Schellens J.H.M.; Wu H.; Sun H.; Silva A.P.; Faris J.; Mataraza J.; Cameron S.; Bauer T.M.Journal for ImmunoTherapy of Cancer5446
692019Nuclear Factor-κB Overexpression is Correlated with Poor Outcomes after Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder CancerCHIANG, YUN ; Wang, Chung-Chieh; YU-CHIEH TSAI ; CHAO-YUAN HUANG ; YEONG-SHIAU PU ; CHIA-CHI LIN ; CHIA-HSIEN CHENG Journal of clinical medicine87
702019Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint InhibitorsJHE-CYUAN GUO ; CHIA-CHI LIN ; Lin, Chen Yuan; MIN-SHU HSIEH ; HUNG-YANG KUO ; Lien, Ming Yu; YU-YUN SHAO ; Ta-Chen Huang ; CHIH-HUNG HSU Anticancer research2829
712019Should we design clinical trials differently in the era of cancer immunotherapy?CHIA-CHI LIN Journal of Immunotherapy and Precision Oncology30
722019ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non–small-cell lung cancerShaw A.T.; Solomon B.J.; Besse B.; Bauer T.M.; CHIA-CHI LIN ; Soo R.A.; Riely G.J.; Ignatius Ou S.-H.; Clancy J.S.; Li S.; Abbattista A.; Thurm H.; Satouchi M.; Camidge D.R.; Kao S.; Chiari R.; Gadgeel S.M.; Felip E.; Martini J.-F.Journal of Clinical Oncology264208
732019Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid TumorsDoi T.; CHIH-HSIN YANG ; Shitara K.; Naito Y.; ANN-LII CHENG ; Sarashina A.; Pronk L.C.; Takeuchi Y.; CHIA-CHI LIN Targeted Oncology2114
742019Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatmentSHAO-LUN LU ; Feng-Ming Hsu ; CHIAO-LING TSAI ; JANG-MING LEE ; PEI-MING HUANG ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YIH-LEONG CHANG ; MIN-SHU HSIEH ; CHIA-HSIEN CHENG European Journal of Surgical Oncology97
752019Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective StudyWEI-LI MA ; CHIA-CHI LIN ; FENG-MING HSU ; JANG-MING LEE ; JIN-SHING CHEN ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Chao Y.-T.; Chang C.-H.; CHIH-HSIN YANG Clinical Lung Cancer99
762019Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinomaTa-Chen Huang ; CHIA-CHI LIN ; Wu Y.-C.; CHIA-HSIEN CHENG ; JANG-MING LEE ; HSIU-PO WANG ; PEI-MING HUANG ; Feng-Ming Hsu ; KUN-HUEI YEH ; ANN-LII CHENG ; KAI-YUAN TZEN ; CHIH-HUNG HSU Journal of the Formosan Medical Association86
772019An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular CarcinomaEl Dika I.; Lim H.Y.; Yong W.P.; CHIA-CHI LIN ; Yoon J.-H.; Modiano M.; Freilich B.; Choi H.J.; Chao T.-Y.; Kelley R.K.; Brown J.; Knox J.; Ryoo B.-Y.; Yau T.; Abou-Alfa G.K.Oncologist6759
782019Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancerMehnert J.M.; Varga A.; Brose M.S.; Aggarwal R.R.; CHIA-CHI LIN ; Prawira A.; De Braud F.; Tamura K.; Doi T.; Piha-Paul S.A.; Gilbert J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Keam B.BMC Cancer122108
792019A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomasCHIA-CHI LIN ; Arkenau H.-T.; Lu S.; Sachdev J.; de Castro Carpe?o J.; Mita M.; Dziadziuszko R.; Su W.-C.; Bobilev D.; Hughes L.; Chan J.; Zhang Z.-Y.; Weiss G.J.British Journal of Cancer1512
802019Challenges of the phase I drug development in non-small cell lung cancerCHIA-CHI LIN Chinese Clinical Oncology78
812019Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patientsZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; CHIA-CHI LIN ; CHIH-HSIN YANG ; CHONG-JEN YU European Journal of Cancer2724
822019Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trialShaw A.T.; Solomon B.J.; Chiari R.; Riely G.J.; Besse B.; Soo R.A.; Kao S.; CHIA-CHI LIN ; Bauer T.M.; Clancy J.S.; Thurm H.; Martini J.-F.; Peltz G.; Abbattista A.; Li S.; Ou S.-H.I.The Lancet Oncology232173
832018A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinomaSHIH-HUNG YANG ; YU-YUN SHAO ; CHIA-CHI LIN ; SUNG-HSIN KUO ; ANN-LII CHENG ; KUN-HUEI YEH Anticancer Research32
842018Management of Toxicities of Targeted TherapiesCHIH-HSIN YANG ; CHIA-CHI LIN ; CHIA-YU CHU IASLC Thoracic Oncology40
852018Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitorsBIN-CHI LIAO ; Bai Y.-Y; JIH-HSIANG LEE ; CHIA-CHI LIN ; SHU-YUNG LIN ; YEE-FAN LEE ; CHAO-CHI HO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG Journal of the Formosan Medical Association119
862018Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studySolomon B.J.; Besse B.; Bauer T.M.; Felip E.; Soo R.A.; Camidge D.R.; Chiari R.; Bearz A.; CHIA-CHI LIN ; Gadgeel S.M.; Riely G.J.; Tan E.H.; Seto T.; James L.P.; Clancy J.S.; Abbattista A.; Martini J.-F.; Chen J.; Peltz G.; Thurm H.; Ignatius Ou S.-H.; Shaw A.T.The Lancet Oncology572458
872018Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer PatientsWu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE ; CHIA-CHI LIN ; WEI-YU LIAO ; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG Clinical Lung Cancer1617
882018Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapyJHE-CYUAN GUO ; CHIA-CHI LIN ; Ta-Chen Huang ; PEI-MING HUANG ; HUNG-YANG KUO ; Chang C.-H.; CHIA-CHUN WANG ; CHIA-HSIEN CHENG ; KUN-HUEI YEH ; CHIH-HUNG HSU ; JANG-MING LEE Anticancer Research1211
892018TAK-264 (MLN0264) in previously treated Asian patients with advanced gastrointestinal carcinoma expressing guanylyl cyclase C: Results from an open-label, non-randomized phase 1 studyBang Y.-J.; Takano T.; CHIA-CHI LIN ; Fasanmade A.; Yang H.; Danaee H.; Asato T.; Kalebic T.; Wang H.; Doi T.Cancer Research and Treatment76
902018Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in TaiwanSHU-YUNG LIN ; Yang C.-Y.; BIN-CHI LIAO ; CHAO-CHI HO ; WEI-YU LIAO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Hsu W.-H.; KANG-YI SU ; YIH-LEONG CHANG ; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU Journal of Cancer4041
912018Using Ion Torrent sequencing to study genetic mutation profiles of fatal thyroid cancersJIN-YING LU ; WERN-CHERNG CHENG ; KUEN-YUAN CHEN ; CHIA-CHI LIN ; CHING-CHUNG CHANG ; KUAN-TING KUO ; PEI-LUNG CHEN Journal of the Formosan Medical Association31
922018Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012Tahara M.; Muro K.; Hasegawa Y.; Chung H.C.; CHIA-CHI LIN ; Keam B.; Takahashi K.; Cheng J.D.; Bang Y.-J.Cancer Science4142
932018Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG Expert Opinion on Pharmacotherapy55
942018Response to Nivolumab as Salvage Therapy in a Patient with Thymic CarcinomaYang P.-C.; JHE-CYUAN GUO ; MIN-SHU HSIEH ; CHIA-CHI LIN ; CHIH-HUNG HSU Journal of Thoracic Oncology54
952018Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic studyCHIA-CHI LIN ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHAO-CHI HO ; WEI-YU LIAO ; JIH-HSIANG LEE ; TZU-HSIU TSAI ; KANG-YI SU ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Bai Y.-Y.; DE-RUI HUANG ; Thress K.S.; CHIH-HSIN YANG The Lancet Respiratory Medicine120109
962018Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012Mehra R.; Seiwert T.Y.; Gupta S.; Weiss J.; Gluck I.; Eder J.P.; Burtness B.; Tahara M.; Keam B.; Kang H.; Muro K.; Geva R.; Chung H.C.; CHIA-CHI LIN ; Aurora-Garg D.; Ray A.; Pathiraja K.; Cheng J.; Chow L.Q.M.; Haddad R.British Journal of Cancer303256
972018Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?PEI-MING HUANG ; Feng-Ming Hsu ; CHIA-CHI LIN ; Hsu C.-H.; CHIA-HSIEN CHENG ; JANG-MING LEE Digestive Surgery44
982017Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension componentCHIH-HSIN YANG ; Ahn M.-J.; Kim D.-W.; Ramalingam S.S.; Sequist L.V.; Su W.-C.; Kim S.-W.; Kim J.-H.; Planchard D.; Felip E.; Blackhall F.; Haggstrom D.; Yoh K.; Novello S.; Gold K.; Hirashima T.; Chia-Chi Lin ; Mann H.; Cantarini M.; Ghiorghiu S.; Jänne P.A.Journal of Clinical Oncology452443
992017Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialPetrylak D.P.; de Wit R.; Chi K.N.; Drakaki A.; Sternberg C.N.; Nishiyama H.; Castellano D.; Hussain S.; Fl?chon A.; Bamias A.; Yu E.Y.; Lee Y.-G.; Cort?s L.V.; Flores C.L.U.; Blaisse R.J.B.; Erdkamp F.L.G.; Aarts M.J.B.; Wojcik-Tomaszewska J.; Tomczak P.; Sikora-Kupis B.; Schenker M.; van der Heijden M.S.; Herzal A.A.; Udrea A.A.; Karlov P.; Fomkin R.; Pulido E.G.; Mignorance J.I.D.; Gauna D.C.; Rodr?guez-Vida A.; Su Y.-L.; Lin C.-L.; Matsubara N.; CHIA-CHI LIN ; Yeh S.-P.; ?i?in I.; Erman M.; Urun Y.; Golovko Y.; Bondarenko I.; Sinielnikov I.; Crabb S.; Syndikus I.; Alekseev B.; Huddart R.; Sundar S.; Chowdhury S.; Sarwar N.; Flaig T.; Pan C.X.; Schwarz J.; Cultrera J.; Hainsworth J.; Herms B.; Necchi A.; Lawler W.; Lowe T.; Tagawa S.; Aragon-Ching J.; Vaishampayan U.; G?czi L.; Ou Y.-C.; Coskun H.S.; Su W.-P.; Hegemann M.; Percent I.J.; Lee J.-L.; Tucci M.; Semenov A.; Laestadius F.; Peer A.; Tortora G.; Safina S.; del Muro X.G.; Rodriguez-Vida A.; Cicin I.; Harputluoglu H.; Widau R.C.; Liepa A.M.; Walgren R.A.; Hamid O.; Zimmermann A.H.; Bell-McGuinn K.M.; Powles T.; Wong S.-L.S.; Tan T.H.; Hovey E.J.; Clay T.D.; Ng S.S.W.; Rutten A.; Machiels J.-P.; Dumez H.; Cheng S.Y.-S.; Ferrario C.; Sengeloev L.; Jensen N.V.; Thibault C.; Laguerre B.; Joly F.; Flechon A.; Culine S.; Becht C.; Niegisch G.; St?ckle M.; Grimm M.-O.; Gakis G.; Schultze-Seemann W.; Kalofonos H.; Mavroudis D.; Papandreou C.; Karavasilis V.; R?v?sz J.; Geczi L.; Rosenbaum E.; Leibowitz-Amit R.; Kejzman D.; Sarid D.; Scagliotti G.V.; Bracarda S.; Massari F.; Osawa T.; Miyajima N.; Shinohara N.; Fukuta F.; Ohyama C.; Obara W.; Yamashita S.; Tomita Y.; Kawai K.; Fukasawa S.; Oyama M.; Yonese J.; Nagata M.; Uemura M.; Nishimura K.; Kawakita M.; Tsunemori H.; Hashine K.; Inokuchi J.; Yokomizo A.; Nagamori S.; Lee H.J.; Park S.H.; Rha S.Y.; Kim Y.J.The Lancet137122
1002017Timing of multikinase inhibitor initiation in differentiated thyroid cancerBrose M.S.; Smit J.; CHIA-CHI LIN ; Pitoia F.; Fellous M.; De Sanctis Y.; Schlumberger M.; Tori M.; Sugitani I.Endocrine-Related Cancer2927
1012017New data on clinical decisions in NSCLC patients with uncommon EGFR mutationsWu T.; Hsiue E.H.; JIH-HSIANG LEE ; Chia-Chi Lin ; CHIH-HSIN YANG Expert Review of Respiratory Medicine1514
1022017Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapyBIN-CHI LIAO ; Chia-Chi Lin ; JIH-HSIANG LEE ; CHIH-HSIN YANG Lung Cancer3835
1032017Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion studyAhn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; CHIA-CHI LIN ; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG The Lancet Respiratory Medicine8167
1042017A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvementYUN CHIANG ; CHIA-HSIEN CHENG ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; Chia-Chi Lin ; CHIH-HUNG HSU ; ANN-LII CHENG ; YEONG-SHIAU PU Journal of the Formosan Medical Association76
1052017Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of AfatinibBIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG Current Oncology Reports1919
1062017Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinibZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; Chia-Chi Lin ; CHIH-HSIN YANG ; CHONG-JEN YU Oncologist2525
1072017A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerReynolds K.L.; Bedard P.L.; Lee S.-H.; Chia-Chi Lin ; Tabernero J.; Alsina M.; Cohen E.; Baselga J.; Blumenschein G.; Graham D.M.; Garrido-Laguna I.; Juric D.; Sharma S.; Salgia R.; Seroutou A.; Tian X.; Fernandez R.; Morozov A.; Sheng Q.; Ramkumar T.; Zubel A.; Bang Y.-J.BMC Cancer2221
1082017Optimal usage of radium-223 in metastatic castration-resistant prostate cancerCha T.-L.; Wu T.T.-L.; Vogelzang N.J.; CHAO-YUAN HUANG ; Huang S.-P.; CHIA-CHI LIN ; Ou Y.-C.; Pang S.-T.; Shen D.H.-Y.; Wu W.-J.; Chang W.Y.-H.Journal of the Formosan Medical Association1514
1092016Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non-small cell lung cancerChen, Kai-Lung; CHIA-CHI LIN ; YUNG-TSU CHO ; Yang, Che-Wen; YI-SHUAN SHEEN ; Tsai, Hsiao-En; CHIA-YU CHU JAMA Dermatology2920
1102016151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIsBIN-CHI LIAO ; Bai Y.-Y.; CHIA-CHI LIN ; SHU-YUNG LIN ; YEE-FAN LEE ; CHAO-CHI HO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG Journal of Thoracic Oncology11
1112016Safety of gefitinib in non-small cell lung cancer treatmentHsiue E.H.-C.; JIH-HSIANG LEE ; CHIA-CHI LIN ; CHIH-HSIN YANG Expert Opinion on Drug Safety1915
1122016Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)Motzer R.J.; Alyasova A.; Ye D.; Karpenko A.; Li H.; Alekseev B.; Xie L.; Kurteva G.; Kowalyszyn R.; Karyakin O.; Neron Y.; Cosgriff T.; Collins L.; Brechenmacher T.; CHIA-CHI LIN ; Morgan L.; Yang L.Annals of Oncology3534
1132016Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohortChow L.Q.M.; Haddad R.; Gupta S.; Mahipal A.; Mehra R.; Tahara M.; Berger R.; Eder J.P.; Burtness B.; Lee S.-H.; Keam B.; Kang H.; Muro K.; Weiss J.; Geva R.; CHIA-CHI LIN ; Chung H.C.; Meister A.; Dolled-Filhart M.; Pathiraja K.; Cheng J.D.; Seiwert T.Y.Journal of Clinical Oncology657141
1142016Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialMuro K.; Chung H.C.; Shankaran V.; Geva R.; Catenacci D.; Gupta S.; Eder J.P.; Golan T.; Le D.T.; Burtness B.; McRee A.J.; CHIA-CHI LIN ; Pathiraja K.; Lunceford J.; Emancipator K.; Juco J.; Koshiji M.; Bang Y.-J.The Lancet Oncology869787
1152016Obesity and outcomes in patients with metastatic urothelial carcinomaLeiter A.; Doucette J.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Bamias A.; Oh W.K.; Galsky M.D.Bladder Cancer60
1162016Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumorsMinami H.; Ando Y.; Ma B.B.Y.; Hsiang Lee J.; Momota H.; Fujiwara Y.; Li L.; Fukino K.; Ito K.; Tajima T.; Mori A.; CHIA-CHI LIN Cancer Science1715
1172016Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: Results of an international randomized phase II trial (JASINT1)De Santis M.; Wiechno P.J.; Bellmunt J.; Lucas C.; Su W.-C.; Albiges L.; CHIA-CHI LIN ; Senkus-Konefka E.; Flechon A.; Mourey L.; Necchi A.; Loidl W.C.; Retz M.M.; Vaissi?re N.; Culine S.Annals of Oncology4639
1182016Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitorsBIN-CHI LIAO ; CHIA-CHI LIN ; JIH-HSIANG LEE ; CHIH-HSIN YANG Journal of Biomedical Science4237
1192016Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancerHsiue E.H.-C; JIH-HSIANG LEE ; CHIA-CHI LIN ; CHIH-HSIN YANG Expert Review of Molecular Diagnostics1514
1202016Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 studyCHIH-HSIN YANG ; Srimuninnimit V; Ahn M.-J; CHIA-CHI LIN ; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K.Journal of Thoracic Oncology2220
1212015Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinomaJHE-CYUAN GUO ; Ta-Chen Huang ; CHIA-CHI LIN ; MIN-SHU HSIEH ; Chang C.-H.; PEI-MING HUANG ; JANG-MING LEE ; Feng-Ming Hsu ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; KUN-HUEI YEH ; ANN-LII CHENG ; CHIH-HUNG HSU Journal of Thoracic Oncology1516
1222015Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinomaCHIA-CHUN WANG ; CHIA-HSIEN CHENG ; CHIAO-LING TSAI ; JANG-MING LEE ; PEI-MING HUANG ; CHIA-CHI LIN ; CHIH-HUNG HSU ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Feng-Ming Hsu Radiotherapy and Oncology98
1232015Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategyBIN-CHI LIAO ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG Therapeutic Advances in Medical Oncology1616
1242015RECORD-2: Phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinomaRavaud A.; Barrios C.H.; Alekseev B.; Tay M.-H.; Agarwala S.S.; Yalcin S.; CHIA-CHI LIN ; Roman L.; Shkolnik M.; Anak O.; Gogov S.; Pelov D.; Louveau A.-L.; Melichar B.Annals of Oncology6657
1252015Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: Pharmacokinetics and recommended phase 2 doseVenkatakrishnan K.; Kim T.M.; CHIA-CHI LIN ; Thye L.S.; Chng W.J.; Ma B.; Chen M.H.; Zhou X.; Liu H.; Kelly V.; Kim W.S.Investigational New Drugs2627
1262015Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal CarcinomatosisBIN-CHI LIAO ; JIH-HSIANG LEE ; CHIA-CHI LIN ; YA-FANG CHEN ; Chang C.-H.; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG Journal of Thoracic Oncology137113
1272015Systematic review and network meta-analysis: Neoadjuvant chemoradiotherapy for locoregional esophageal cancerTa-Chen Huang ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YU-KANG TU Japanese Journal of Clinical Oncology3027
1282015Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancerBIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG Current Opinion in Oncology122109
1292014Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancerGalsky M.D.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.H.; Moshier E.; Sonpavde G.; Godbold J.; Oh W.K.; Bamias A.Urologic Oncology: Seminars and Original Investigations227
1302014A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignanciesCHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG British Journal of Cancer6264
1312014An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerStadler W.M.; Vaughn D.J.; Sonpavde G.; Vogelzang N.J.; Tagawa S.T.; Petrylak D.P.; Rosen P.; CHIA-CHI LIN ; Mahoney J.; Modi S.; Lee P.; Ernstoff M.S.; Su W.-C.; Spira A.; Pilz K.; Vinisko R.; Schloss C.; Fritsch H.; Zhao C.; Carducci M.A.Cancer7673
1322014Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapyGalsky M.D.; Moshier E.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Pond G.; Godbold J.; Oh W.K.; Bamias A.Urologic Oncology: Seminars and Original Investigations114
1332014Phase II results of dovitinib (TKI258) in patients with metastatic renal cell cancerEscudier B.; Gr?nwald V.; Ravaud A.; Ou Y.-C.; Castellano D.; CHIA-CHI LIN ; Gschwend J.E.; Harzstark A.; Beall S.; Pirotta N.; Squires M.; Shi M.; Angevin E.Clinical Cancer Research4844
1342014A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumorsGhamande S.; CHIA-CHI LIN ; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; CHIH-HSIN YANG ; ANN-LII CHENG ; Ghalib M.H.; Chuadhary I.; Goel S.Investigational New Drugs2315
1352014First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trialCHIH-HSIN YANG ; Kang J.H.; Mok T.; Ahn M.-J.; Srimuninnimit V.; CHIA-CHI LIN ; Kim D.-W.; Tsai C.-M.; Barraclough H.; Altug S.; Orlando M.; Park K.European Journal of Cancer4140
1362014Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancerJIH-HSIANG LEE ; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; YEUN-CHUNG CHANG ; CHONG-JEN YU ; JIN-YUAN SHIH ; CHIA-CHI LIN ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; PAN-CHYR YANG ; CHIH-HSIN YANG Journal of Thoracic Oncology4435
1372013Scalp melanoma in a woman with LEOPARD syndrome: Possible implication of PTPN11 signaling in melanoma pathogenesisCheng Y.-P.; HSIEN-YI CHIU ; Hsiao T.-L.; Hsiao C.-H.; CHIA-CHI LIN ; YI-HUA LIAO Journal of the American Academy of Dermatology1511
1382013Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapyWEI-WU CHEN ; CHIA-CHI LIN ; TA-CHEN HUANG ; ANN-LII CHENG ; KUN-HUEI YEH ; CHIH-HUNG HSU Anticancer Research1111
1392013Reply to S. ValeCHIA-CHI LIN ; JANN-YUAN WANG ; YEONG-SHIAU PU Journal of Clinical Oncology00
1402013Phase i study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinomaAngevin E.; Lopez-Martin J.A.; CHIA-CHI LIN ; Gschwend J.E.; Harzstark A.; Castellano D.; Soria J.-C.; Sen P.; Chang J.; Shi M.; Kay A.; Escudier B.Clinical Cancer Research112105
1412013Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trialSmith D.C.; Smith M.R.; Sweeney C.; Elfiky A.A.; Logothetis C.; Corn P.G.; Vogelzang N.J.; Small E.J.; Harzstark A.L.; Gordon M.S.; Vaishampayan U.N.; Haas N.B.; Spira A.I.; Lara Jr. P.N.; CHIA-CHI LIN ; Srinivas S.; Sella A.; Sch?ffski P.; Scheffold C.; Weitzman A.L.; Hussain M.Journal of Clinical Oncology374346
1422013EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancerHSIANG-FONG KAO ; CHIA-CHI LIN ; CHIH-HSIN YANG Future Oncology76
1432013First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developmentsBIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG Drugs1516
1442013The impact of gender on outcomes in patients with metastatic urothelial carcinomaHaines L.; Bamias A.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.H.; Moshier E.; Sonpavde G.; Godbold J.; Oh W.K.; Galsky M.D.Clinical Genitourinary Cancer1916
1452013Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapyGalsky M.D.; Moshier E.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Godbold J.; Oh W.K.; Bamias A.Cancer8072
1462013Case reportCHIA-CHI LIN ; JANN-YUAN WANG ; YEONG-SHIAU PU Journal of Clinical Oncology67
1472013Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapyGalsky M.D.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Moshier E.; Sonpavde G.; Godbold J.; Oh W.K.; Bamias A.Cancer99
1482012A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumorSHIH-HUNG YANG ; CHIA-CHI LIN ; ZHONG-ZHE LIN ; Tseng Y.-L.; RUEY-LONG HONG Investigational New Drugs3428
1492011RET mutations and medullary thyroid cancerCHIA-CHI LIN Journal of the Formosan Medical Association20
1502011PR-104 plus sorafenib in patients with advanced hepatocellular carcinomaAbou-Alfa G.K.; Chan S.L.; CHIA-CHI LIN ; Chiorean E.G.; Holcombe R.F.; Mulcahy M.F.; Carter W.D.; Patel K.; Wilson W.R.; Melink T.J.; Gutheil J.C.; Tsao C.-J.Cancer Chemotherapy and Pharmacology2625
1512011Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgeryJANG-MING LEE ; Yang S.-Y.; Yang P.-W.; CHIA-TUNG SHUN ; Wu M.-T.; CHIH-HUNG HSU ; CHIA-CHI LIN ; CHIA-HSIEN CHENG ; Wang Y.-H.; Chuang T.-H.; JIN-SHING CHEN ; HSAO-HSUN HSU ; PEI-MING HUANG ; SHUENN-WEN KUO ; Lee Y.-C.Annals of Surgical Oncology2119
1522011Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutationsCHIA-CHI LIN ; CHIH-HSIN YANG Drugs1010
1532011Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinomaFeng-Ming Hsu ; JANG-MING LEE ; PEI-MING HUANG ; CHIA-CHI LIN ; CHIH-HUNG HSU ; YU-CHIEH TSAI ; Lee Y.-C.; CHIA-HSIEN CHENG International Journal of Radiation Oncology Biology Physics3836
1542011Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patientsNg C.M.; Patnaik A.; Beeram M.; CHIA-CHI LIN ; Takimoto C.H.Cancer Chemotherapy and Pharmacology2410
1552011Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLCMedema R.H.; CHIA-CHI LIN ; CHIH-HSIN YANG Clinical Cancer Research6058
1562010Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.YU-YUN SHAO ; CHIA-CHI LIN ; CHIH-HSIN YANG Discovery medicine1312
1572010Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptorsCHIA-CHI LIN ; Hsu H.-H.; Sun C.-T.; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; CHONG-JEN YU ; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; CHIH-HSIN YANG ; Mok T.Journal of Thoracic Oncology2622
1582010Cross-cultural adaptation and validation of the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0): The development of the Taiwanese versionHUI-FEN MAO ; Chen, W.-Y.; Yao, G.; SHEAU-LING HUANG ; CHIA-CHI LIN ; KAI-PING GRACE YAO Clinical Rehabilitation2926
1592009Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomyFeng-Ming Hsu ; Lee Y.-C.; JANG-MING LEE ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YU-CHIEH TSAI ; Wu J.-K.; CHIA-HSIEN CHENG Annals of Surgical Oncology3332
1602009Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder CancerCHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; Feng-Ming Hsu ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU International Journal of Radiation Oncology Biology Physics2722
1612009Atorvastatin induces thrombomodulin expression in the aorta of cholesterol-fed rabbits and in TNFα-treated human aortic endothelial cellsLin S.-J.; Hsieh F.-Y.; Chen Y.-H.; CHIA-CHI LIN ; Kuan I.-I.; SHU-HUEI WANG ; CHAU-CHUNG WU ; Chien H.-F.; Lin F.-Y.; YUH-LIEN CHEN Histology and Histopathology2020
1622009Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancerCHIA-CHI LIN ; CHIH-HSIN YANG Targeted Oncology119
1632009National Center of Excellence for Clinical Trials and Research at National Taiwan University HospitalCHIA-CHI LIN ; CHIH-HSIN YANG ; ANN-LII CHENG ; Chan W.-K.; HONG-NERNG HO Drug Information Journal32
1642009Phase i study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumorsCHIA-CHI LIN ; Calvo E.; Papadopoulos K.P.; Patnaik A.; Sarantopoulos J.; Mita A.C.; Preston G.G.; Mita M.M.; Rodon J.; Mays T.; Yeh I.-T.; O'Rourke P.; Takimoto C.H.; Dancey J.E.; Chen H.; Tolcher A.W.Cancer Chemotherapy and Pharmacology1513
1652009Phase i and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignanciesCHIA-CHI LIN ; Beeram M.; Rowinsky E.K.; Takimoto C.H.; Ng C.M.; Geyer Jr. C.E.; Denis L.J.; De Bono J.S.; Hao D.; Tolcher A.W.; Rha S.-Y.; Jolivet J.; Patnaik A.Cancer Chemotherapy and Pharmacology22
1662008Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatmentZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG Lung Cancer51
1672008Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinomaCHIA-CHI LIN ; YEONG-SHIAU PU ; CHIH-HUNG HSU ; Keng H.-Y.; ANN-LII CHENG ; CHIH-HSIN YANG Urologic Oncology: Seminars and Original Investigations87
1682008Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trialCHIUN HSU ; SUNG-HSIN KUO ; Hu F.-C.; ANN-LII CHENG ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIA-CHI LIN ; Huang T.-C.; PAN-CHYR YANG ; CHIH-HSIN YANG Lung Cancer1411
1692008Down-regulated expression of RhoA in human conventional renal cell carcinomaYEONG-SHIAU PU ; Wang C.-W.; Liu G.-Y.; Kuo Y.-Z.; CHAO YUAN HUANG ; Kang W.-Y.; CHIA-TUNG SHUN ; CHIA-CHI LIN ; Wu W.-J.; Hour T.-C.Anticancer Research55
1702008Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized studyFENG-MING HSU ; CHIA-CHI LIN ; JANG-MING LEE ; YIH-LEONG CHANG ; CHIH-HUNG HSU ; YU-CHIEH TSAI ; Lee Y.-C.; CHIA-HSIEN CHENG Journal of Surgical Oncology3229
1712008Systemic therapy for metastatic urothelial carcinomaCHIA-CHI LIN ; CHIH-HUNG HSU ; YEONG-SHIAU PU ; Vogelzang N.J.BJU International73
1722007Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trialCHIA-CHI LIN ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HSIN YANG Investigational New Drugs104103
1732007Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II studyCHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; Keng H.-Y.; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU Anti-Cancer Drugs3229
1742007Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based RegimensCHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU Urology2421
1752007Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinomaCHIA-CHI LIN ; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIUN HSU ; YU-CHIEH TSAI ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HUNG HSU Anti-Cancer Drugs108
1762007Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trialCHIA-CHI LIN ; CHIH-HUNG HSU ; Hour T.-C.; ANN-LII CHENG ; CHAO-YUAN HUANG ; KUO-HOW HUANG ; Chen J.; YEONG-SHIAU PU Urologic Oncology: Seminars and Original Investigations66
1772007Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial CarcinomaCHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; ANN-LII CHENG ; Vogelzang N.J.; YEONG-SHIAU PU Journal of Urology2018
1782007Novel targeted therapies for advanced esophageal cancerCHIA-CHI LIN ; Papadopoulos K.P.Diseases of the Esophagus1212
1792007Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancerCHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; JANG-MING LEE ; KUN-HUEI YEH ; CHIH-HSIN YANG ; Lin J.-T.; ANN-LII CHENG ; Lee Y.-C.Annals of Oncology3836
1802007A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancerCHIA-CHI LIN ; ANN-LII CHENG ; CHIH-HUNG HSU ; YEN-SHEN LU ; CHIUN HSU ; KUN-HUEI YEH ; Wu C.-Y.; CHIUN-SHENG HUANG ; CHIH-HSIN YANG Anticancer Research22
1812006Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancerHour T.-C.; YEONG-SHIAU PU ; CHIA-CHI LIN ; SHI-WEI HUANG ; Chen J.; Chiu A.W.; Chen C.-J.; CHAO-YUAN HUANG Anticancer Research108
1822006Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicityCHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; ANN-LII CHENG ; Chen J.; Vogelzang N.J.; YEONG-SHIAU PU Cancer2424
1832006Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case studyCHIA-CHI LIN ; CHIH-HUNG HSU ; YEONG-SHIAU PU Anticancer Research00
1842006Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cellsYEONG-SHIAU PU ; Hsieh M.-W.; Wang C.-W.; Liu G.-Y.; CHAO-YUAN HUANG ; CHIA-CHI LIN ; Guan J.-Y.; Lin S.-R.; Hour T.-C.Biochemical Pharmacology3835
1852004Changing trends of prostate cancer in AsiaYEONG-SHIAU PU ; Chiang H.-S.; CHIA-CHI LIN ; CHAO-YUAN HUANG ; KUO-HOW HUANG ; Chen J.Aging Male1030
1862004Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxideHour T.-C.; CHAO-YUAN HUANG ; CHIA-CHI LIN ; Chen J.; Guan J.-Y.; Lee J.-M.; YEONG-SHIAU PU Anti-Cancer Drugs2423
1872002A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracilCHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; CHIH-HSIN YANG ; YEN-SHEN LU ; CHIA-CHI LIN ; Bu C.-F.; KUN-HUEI YEH Anticancer Research1212
1882002Comparison of bone marrow studies with blood culture for etiological diagnosis of disseminated mycobacterial and fungal infection in patients with acquired immunodeficiency syndromeKer C.-C.; CHIEN-CHING HUNG ; Huang S.-Y.; Chen M.-Y.; SZU-MIN HSIEH ; CHIA-CHI LIN ; SHAN-CHWEN CHANG ; KWEN-TAY LUH Journal of Microbiology, Immunology and Infection300
1892001A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancerCHIA-CHI LIN ; CHIH-HUNG HSU ; Chen J.; Tsai T.-C.; ANN-LII CHENG ; YEONG-SHIAU PU Anticancer Research1413
1902001Genetic characterization of the rotaviruses associated with a nursery outbreakLee C.-N.; CHIA-CHI LIN ; CHUAN-LIANG KAO ; Zao C.-L.; Shih M.-C.; Chen H.-N.Journal of Medical Virology29